Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal

Content Provider	Semantic Scholar
Author	Lin, Shih-Ku Juang, Dong-Juiing Chen, Li-Chin Jann, Michael W.
Copyright Year	1993
Abstract	Haloperidol and reduced haloperidol plasma concentrations were measured in twelve schizophrenic patients upon cessation of haloperidol decanoate (HLD) treatment. Each patient received HLD 100 mg every 4 weeks for five injections. After the fifth injection, HLD was discontinued. Haloperidol and reduced haloperidol plasma concentrations were obtained prior to cessation and at weeks 1, 3, 4, 5, 7, 9, 11, and 13 post-injection. Haloperidol and reduced haloperidol plasma concentrations were assayed by HPLC. Both haloperidol and reduced haloperidol plasma concentrations were detectable 13 weeks post HLD discontinuation. Maximal haloperidol plasma concentrations were observed at one week post cessation and gradually declined. The mean elimination half-life for haloperidol was 27.4 +/- 8.6 days (range 19.0-47.0 days). Reduced haloperidol plasma concentrations declined very slowly. Our results show that both haloperidol and reduced haloperidol plasma concentrations can remain for extended time periods after HLD is discontinued.
Starting Page	35
Ending Page	40
Page Count	6
File Format	PDF HTM / HTML
DOI	10.1016/0920-9964(93)90007-6
PubMed reference number	8461270
Journal	Medline
Volume Number	9
Alternate Webpage(s)	https://api.elsevier.com/content/article/pii/0920996493900076
Alternate Webpage(s)	https://www.sciencedirect.com/science/article/pii/0920996493900076?dgcid=api_sd_search-api-endpoint
Alternate Webpage(s)	https://doi.org/10.1016/0920-9964%2893%2990007-6
Journal	Schizophrenia Research
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article